About: Hartmut Döhner

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hartmut Döhner Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher

Attributes	Values
rdf:type	Item
description	ikertzailea (eu) researcher (en) 연구원 (ko) 研究者 (ja) araştırmacı (tr) wetenschapper (nl) дослідник (uk) वैज्ञानिक (hi) հետազոտող (hy) deutscher Hämatologe und Onkologe (de)
rdfs:label	Hartmut Döhner (de) Hartmut Döhner (en) Hartmut Döhner (nl) Hartmut Döhner (sl) Hartmut Döhner (ast)
skos:prefLabel	Hartmut Döhner (de) Hartmut Döhner (en) Hartmut Döhner (nl) Hartmut Döhner (sl) Hartmut Döhner (ast)
name	Hartmut Döhner (de) Hartmut Döhner (en) Hartmut Döhner (nl) Hartmut Döhner (sl) Hartmut Döhner (ast)
given name	wds:Q66385451-74B2537C-4FB5-4411-8A1D-4E57CF9D3196
given name	Hartmut
instance of	wds:Q66385451-83DCFC27-407C-4AFE-9EE0-46B3302E96B1
instance of	Homo sapiens
occupation	wds:Q66385451-106e5089-4626-55bb-1952-f42e7bfd6ad1 wds:Q66385451-58C11F17-A1BA-4B47-A5FB-5C1305B24C71 wds:Q66385451-5e22673a-40a4-6430-926a-755ee7b62ed4
employer	wds:Q66385451-b58bc687-47ef-0f96-0b1c-44006b93185a
languages spoken, written or signed	wds:Q66385451-0d303ad7-45d0-0124-f54a-48f105fb687a wds:Q66385451-dda3f566-4a4d-fb51-89fd-d69db6a90c58
place of birth	wds:Q66385451-8a666f4f-4a1a-4a9f-1568-5d2b246d8c88
sex or gender	wds:Q66385451-d3e1ccc1-4cfe-0ee7-73d3-898452dd2780
VIAF ID	wds:Q66385451-ad9e3288-4b06-ffba-a78f-04fe3d7ca43a wds:Q66385451-f9eab614-47f9-6c45-1c76-5f8ec6985097
GND ID	wds:Q66385451-0ac728d2-467d-661c-05c2-c3b355ce3338
Library of Congress authority ID	wds:Q66385451-2136d217-42ad-9ebf-0d2a-d3c7e5575c9b
country of citizenship	wds:Q66385451-1c49253c-47fa-c5c3-6272-091962f91f89
date of birth	wds:Q66385451-12033d8f-4e70-e8d1-49e4-eeb69585ad9d
educated at	wds:Q66385451-453dffbc-464f-2207-4df8-b1c9c8dad68b
family name	wds:Q66385451-eb9d8c03-492f-16db-b937-704c1bed1d68
VIAF ID	http://viaf.org/viaf/315710824 http://viaf.org/viaf/52295133
GND ID	https://d-nb.info/gnd/110666585
Library of Congress authority ID	http://id.loc.gov/authorities/names/nb2010023632
occupation	oncologist hematologist researcher
employer	University Hospital Ulm
languages spoken, written or signed	English German
place of birth	Bad Kreuznach
sex or gender	male
VIAF ID	315710824 52295133
GND ID	110666585
Library of Congress authority ID	nb2010023632
country of citizenship	Germany
date of birth	1957-01-01 00:00:00Z (xsd:dateTime)
educated at	Heidelberg University
family name	Döhner
ORCID iD	wds:Q66385451-F14C7BC4-EB6A-416D-98E6-8C7FEB200551
ORCID iD	https://orcid.org/0000-0003-2116-5536
ORCID iD	0000-0003-2116-5536
is owl:sameAs of	Hartmut Döhner
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q66385451 https://de.wikipedia.org/wiki/Hartmut_D%C3%B6hner
is author of	Impact of genetic features on treatment decisions in AML. Progranulin is a novel independent predictor of disease progression and overall survival in chronic lymphocytic leukemia Genomic Classification and Prognosis in Acute Myeloid Leukemia Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy High-dose daunorubicin in older patients with acute myeloid leukemia Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status TP53 mutation and survival in chronic lymphocytic leukemia Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software